Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 6/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | LPL | P06858 | 6/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL750267 | 0.89 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3TP53 | |
| SCHEMBL18549855 | 0.69 | LPL (0.45) | LPLLIPG | |
| SCHEMBL661288 | 0.68 | LPL (0.59) | LPLLIPG | |
| SCHEMBL749355 | 0.68 | SLC6A4 (0.53) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18118019 | 0.67 | LPL (0.40) | EGFRLPLLIPG | |
| SCHEMBL1513136 | 0.67 | PDE1B (0.37) | SLC6A2SLC6A4EGFRLPLLIPG | |
| SCHEMBL20157779 | 0.66 | LPL (0.42) | SLC6A2SLC6A4SLC6A3LPLLIPG | |
| SCHEMBL16722762 | 0.66 | LPL (0.41) | EGFRLPLLIPG | |
| SCHEMBL21730602 | 0.64 | EGFR (0.40) | EGFRLPLLIPG | |
| SCHEMBL4160336 | 0.64 | LIPG (0.69) | LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9604960-B2 | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9034899-B2 | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20150126517-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT | 2015-05-07 | — | — | US | disclosed |
| EP-2429295-B1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | ALBANY MOLECULAR RES INC (US) | 2013-12-25 | — | — | EP | disclosed |
| US-20100292242-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292242-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | NLN, HTR3B, HTR2C | SLC6A2 64/4885SLC6A4 98/4885SLC6A3 87/4885 |
| US-20150126517-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | NLN, HTR3B, HTR2C | SLC6A2 64/4885SLC6A4 98/4885SLC6A3 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.